GlassScriptPhysician profile
Leann L Fox
NPI 1285639609
$1,925.16
in general payments reported to CMS, 2019-2025
31 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $230 · 2021: $298 · 2022: $125 · 2023: $153 · 2024: $304 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.55 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $339.24 | 2019-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $313.16 | 2019-2025 | |
| Pfizer INC. | $275.99 | 2019-2022 | |
| Janssen Biotech, INC. | $200.82 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| Foundation Medicine, INC. | $89.02 | 2020-2021 | |
| Taiho Oncology, INC. | $85.81 | 2019-2024 | |
| Astellas Pharma US INC | $55.70 | 2020-2025 | Padcev |
| Genzyme Corporation | $51.91 | 2020-2023 | |
| Mirati Therapeutics, INC. | $49.82 | 2023-2024 | Krazati |
| Tempus Ai, INC | $46.66 | 2024-2025 | Xt Cdx |
| Janssen Scientific Affairs, LLC | $46.00 | 2019 | |
| Genentech USA, INC. | $36.07 | 2020-2023 | Polivy |
| Array Biopharma INC | $35.84 | 2024 | Braftovi, Mektovi, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $29.79 | 2019 | |
| Eisai INC. | $26.06 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurobindo Pharma USA, INC. | $24.32 | 2019 | |
| Incyte Corporation | $19.82 | 2019 | |
| Intuitive Surgical, INC. | $18.41 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.40 | 2023 | Enhertu |
| Exelixis INC. | $16.48 | 2022 | |
| Cti Biopharma Corp. | $15.38 | 2023 | Vonjo |
| Sobi, INC | $15.34 | 2024 | |
| Emd Serono, INC. | $15.31 | 2025 | |
| Allergan, INC. | $13.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.83 | 2024 | Opdivo |
| Abbvie INC. | $13.16 | 2023 | |
| Global Blood Therapeutics, INC. | $12.69 | 2021 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Morphosys, US INC. | $12.43 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leann Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.